Researchers successfully replaced 16-26 liters of blood plasma from 12 mild cognitive impairment patients with plasma from young donors aged 18-24, marking the first human attempt to mimic rejuvenating parabiosis effects seen in aging rodents. The protocol aimed for "interstitial rejuvenation" by maximizing donor plasma penetration into tissue spaces through tailored dosing schedules. All procedures proved safe and feasible across three different treatment intensities. This represents a significant escalation from previous Alzheimer's trials that only removed old plasma without young donor replacement. The approach builds on rodent studies showing cognitive improvements when old and young animals share blood circulation, potentially offering a more direct translation of these anti-aging mechanisms. However, this small pilot study focused solely on safety rather than efficacy, leaving cognitive benefits unproven. The extreme intervention raises practical concerns about donor availability, cost, and scalability for widespread use. As a preprint awaiting peer review, these preliminary safety findings require independent validation before advancing to larger controlled trials. The work represents ambitious but early-stage exploration of whether young blood components can meaningfully reverse cognitive decline in humans.